Sort   by:  
 Page size 
ProteomicsAntileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive disease with a poor prognosis. Vacuolar protein sorting 34 (VPS34) is a member of the phosphatidylinositol-3-kinase lipid kinase family that controls the canonical autophagy pathway and vesicular trafficking. Using a recently developed specific inhibitor...
ORGANISM(S): Homo sapiens (Human) 
2020-11-11 | PXD016839 | Pride
Vps34-in1 Autophagy L-asparaginase Vps34 Human molm-14 cells Orbitrap fusion Aml 
UnknownAntileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia.
Not available
S-EPMC7581748 | biostudies-literature
UnknownVPS34-IN1 potentiates STING-dependent activation in human CAL-1 cells.
Not available
S-EPMC12910983 | biostudies-literature
UnknownCharacterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.
Not available
S-EPMC4209782 | biostudies-literature
UnknownEarly Endosomal Vps34-Derived Phosphatidylinositol-3-Phosphate Is Indispensable for the Biogenesis of the Endosomal Recycling Compartment.
Not available
S-EPMC8946653 | biostudies-literature
UnknownSuppression of SARS-CoV-2 infection in ex-vivo human lung tissues by targeting class III phosphoinositide 3-kinase.
Not available
S-EPMC7675438 | biostudies-literature
UnknownEndosomal Phosphatidylinositol-3-Phosphate-Associated Functions Are Dispensable for Establishment of the Cytomegalovirus Pre-Assembly Compartment but Essential for the Virus Growth.
Not available
S-EPMC8398575 | biostudies-literature
UnknownAMPK activation does not enhance autophagy in neurons in contrast to MTORC1 inhibition: different impact on β-amyloid clearance.
Not available
S-EPMC8032230 | biostudies-literature
ProteomicsBortezomib abrogates temozolomide-induced autophagic flux and kills glioblastoma cells through an ATG5 and ATG7 dependent pathway
Glioblastoma (GBM) carries a dismal prognosis largely due to acquired resistance to the standard treatment, which incorporates the chemotherapy temozolomide (TMZ). Inhibiting the proteasomal pathway is an emerging strategy, where combination treatments are under clinical investigation. We hypothesiz...
ORGANISM(S): Homo sapiens (Human) 
2023-03-10 | PXD021828 | Pride
Bortezomib abrogates temozolomide-induced autophagic flux and kills glioblastoma cells through an atg5 and atg7 dependent pathway 
UnknownAutophagic Induction Greatly Enhances Leishmania major Intracellular Survival Compared to Leishmania amazonensis in CBA/j-Infected Macrophages.
Not available
S-EPMC6104192 | biostudies-literature
Sort   by:  
 Page size